ArticleScientific reports2025
Awareness of HPV, HPV vaccine and HPV-associated cancers among Arab Americans.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the awareness of HPV, HPV vaccine and HPV-associated cancers among Arab Americans. This was a cross-sectional study conducted between March and July 2023 among self-identifying Arab Americans residing in Southeast Michigan (n = 295). Adjusted multivariable logistic regression models estimated the associations between HPV, the vaccine and HPV-associated cancers (cervical, anal, oropharyngeal, penile, vaginal, and vulvar) awareness and sociodemographic and behavioral factors. Awareness of HPV-associated cancers were as follows: cervical (50.5%), vaginal (48.4%), vulvar (42.4%), penile (41.5%), anal (41.5%), and oropharyngeal (37.9%) cancers. In the multivariable logistic regression models, compared to females, males had lower odds of being aware that HPV can cause cervical (aOR = 0.38; 95% CI: 0.20–0.73), anal (aOR = 0.50; 95% CI: 0.26–0.95), vaginal (aOR = 0.40; 95% CI: 0.21–0.76), and vulvar (aOR = 0.51; 95% CI: 0.27–0.97) cancers. Similarly, respondents with some college/associate degree had lower odds of being aware that HPV can cause cervical (aOR = 0.31; 95% CI: 0.14–0.69), anal (aOR = 0.31; 95% CI: 0.14–0.70), oropharyngeal (aOR = 0.34; 95% CI: 0.15–0.80), penile (aOR = 0.32; 95% CI: 0.14–0.71), vaginal (aOR = 0.30; 95% CI: 0.14–0.66), and vulvar (aOR = 0.34; 95% CI: 0.15–0.75) cancers compared to those with college degrees. This underscores the necessity for targeted interventions to improve awareness among this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.